Form 4: Calidi Biotherapeutics Director George Peoples Granted Stock Options
SEC Form 4 Filing
Director George Peoples of Calidi Biotherapeutics was granted 30,904 non-qualified stock options on July 1, 2024, according to a Form 4 filing.
Summary
- On July 1, 2024, George Peoples, a director of Calidi Biotherapeutics, received 30,904 non-qualified stock options.
- The exercise price for these options is $0.193 per share, which was the closing price of Calidi Biotherapeutics' common stock on the grant date.
- The options vest monthly over three years, starting from the grant date, under the company's 2023 Equity Incentive Plan.
- The options expire on 07/01/2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The granting of stock options is a routine event. It indicates confidence in the company's future, but it's not overwhelmingly positive or negative.
Positives
- The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.
Future Outlook
The vesting schedule of the options (1/36 per month over three years) suggests a long-term commitment from the director.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning the interests of employees and directors with those of the shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
- The vesting schedule of 3 years is a common vesting period for stock options.
- Comparing the size of the grant to similar companies would require further analysis of Calidi Biotherapeutics' compensation policies and market capitalization.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Grant date of 30,904 non-qualified stock options at an exercise price of $0.193. |
| 07/11/2024 | Date of Form 4 filing. |
| 07/01/2034 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.